Literature DB >> 15752369

Liver X receptor agonists inhibit tissue factor expression in macrophages.

Naoki Terasaka1, Ayano Hiroshima, Akiko Ariga, Shoko Honzumi, Tadashi Koieyama, Toshimori Inaba, Toshihiko Fujiwara.   

Abstract

Exposure of blood to tissue factor (TF) rapidly initiates the coagulation serine protease cascades. TF is expressed by macrophages and other types of cell within atherosclerotic lesions and plays an important role in thrombus formation after plaque rupture. Macrophage TF expression is induced by pro-inflammatory stimuli including lipopolysaccharide (LPS), interleukin-1beta and tumor necrosis factor-alpha. Here we demonstrate that activation of liver X receptors (LXRs) LXRalpha and LXRbeta suppresses TF expression. Treatment of mouse peritoneal macrophages with synthetic LXR agonist T0901317 or GW3965 reduced TF expression induced by pro-inflammatory stimuli. LXR agonists also suppressed TF expression and its activity in human monocytes. Human and mouse TF promoters contain binding sites for the transcription factors AP-1, NFkappaB, Egr-1 and Sp1, but no LXR-binding sites could be found. Cotransfection assays with LXR and TF promoter constructs in RAW 264.7 cells revealed that LXR agonists suppressed LPS-induced TF promoter activity. Analysis of TF promoter also showed that inhibition of TF promoter activity by LXR was at least in part through inhibition of the NFkappaB signaling pathway. In addition, in vivo, LXR agonists reduced TF expression within aortic lesions in an atherosclerosis mouse model as well as in kidney and lung in mice stimulated with LPS. These findings indicate that activation of LXR results in reduction of TF expression, which may influence atherothrombosis in patients with vascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15752369     DOI: 10.1111/j.1742-4658.2005.04599.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  22 in total

1.  Modification in oxidative stress, inflammation, and lipoprotein assembly in response to hepatocyte nuclear factor 4alpha knockdown in intestinal epithelial cells.

Authors:  Valérie Marcil; Ernest Seidman; Daniel Sinnett; François Boudreau; Fernand-Pierre Gendron; Jean-François Beaulieu; Daniel Ménard; Louis-Philippe Precourt; Devendra Amre; Emile Levy
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

Review 2.  Liver X receptors as integrators of metabolic and inflammatory signaling.

Authors:  Noam Zelcer; Peter Tontonoz
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

Review 3.  Cell signaling and nuclear receptors: new opportunities for molecular pharmaceuticals in liver disease.

Authors:  Jeff L Staudinger; Kristin Lichti
Journal:  Mol Pharm       Date:  2007-12-27       Impact factor: 4.939

4.  The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro.

Authors:  H Scholz; T Lund; M K Dahle; J L Collins; O Korsgren; J E Wang; A Foss
Journal:  Diabetologia       Date:  2009-05-05       Impact factor: 10.122

5.  Activation of liver X receptors suppresses inflammatory gene expressions and transcriptional corepressor clearance in rheumatoid arthritis fibroblast like synoviocytes.

Authors:  Chong-Hyeon Yoon; Yong-Jin Kwon; Sang-Won Lee; Yong-Beom Park; Soo-Kon Lee; Min-Chan Park
Journal:  J Clin Immunol       Date:  2012-09-19       Impact factor: 8.317

6.  Coronary heart disease: Significance of liver X receptor α genomics.

Authors:  Vivek Priy Dave; Deepak Kaul
Journal:  World J Cardiol       Date:  2010-06-26

Review 7.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

8.  GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats.

Authors:  C E Leik; N L Carson; J K Hennan; M D Basso; Q-Y Liu; D L Crandall; P Nambi
Journal:  Br J Pharmacol       Date:  2007-04-10       Impact factor: 8.739

9.  Effects of Liver x receptor agonist treatment on signal transduction pathways in acute lung inflammation.

Authors:  Concetta Crisafulli; Emanuela Mazzon; Irene Paterniti; Maria Galuppo; Placido Bramanti; Salvatore Cuzzocrea
Journal:  Respir Res       Date:  2010-02-22

10.  Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense.

Authors:  Kathleen Smoak; Jennifer Madenspacher; Samithamby Jeyaseelan; Belinda Williams; Darlene Dixon; Katie R Poch; Jerry A Nick; G Scott Worthen; Michael B Fessler
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.